Idalazide

Olmesartan medoxomil, the active ingredient in Idalazide, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH USA supplies Idalazide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Idalazide is an antihypertensive medication that acts on the renin‑angiotensin system and promotes diuresis to lower blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure and helps prevent cardiovascular complications. - Essential high blood pressure: provides sustained control when monotherapy is insufficient. - Elevated arterial pressure: improves overall hemodynamic stability.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first dose. - Headache: mild to moderate intensity. - Fatigue: general tiredness without exertion. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Cough: occasional dry throat irritation.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Acute kidney injury: sudden reduction in renal function. - Hyperkalemia: elevated potassium that may affect heart rhythm. - Angioedema: swelling of face, lips, or airway. - Pancreatitis: abdominal pain with elevated enzymes. - Liver dysfunction: abnormal liver enzyme elevations.

Before initiating Idalazide, consider the following precautions: - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: evaluate serum creatinine and eGFR regularly. - Electrolyte surveillance: check potassium and sodium levels, especially with concomitant drugs. - Pregnancy safety: avoid use unless benefits outweigh potential risks, as safety data are limited. - Drug‑specific contraindications: do not use in patients with known hypersensitivity to either component. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Idalazide may interact with several medicines; awareness of these interactions helps maintain safety and efficacy.

Major Interactions (Avoid): - Aliskiren: combined use can cause severe hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: increased lithium levels may lead to toxicity. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, may cause hypotension. - NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance blood‑pressure reduction. - Calcium channel blockers: additive hypotensive effect. - Antidiabetic agents: diuretic may affect glucose control. - Antimicrobials (e.g., trimethoprim): may increase risk of electrolyte disturbances.